BG
SYRE icon

Bellevue Group’s Spyre Therapeutics SYRE Stock Holding History

Bellevue Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4M Buy
+229,931
New +$16.8M 0.43% 52

Other funds holding SYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bellevue Group's SYRE Position: Q2 2026 in Review

Bellevue Group opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 229,931 shares worth $20.4M. The stake represents 0.43% of the portfolio and ranks #52 among its holdings.

215 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Bellevue Group held 229,931 shares of Spyre Therapeutics worth $20.4M as of Q2 2026.
  • Spyre Therapeutics was a new Bellevue Group position in Q2 2026.
  • Spyre Therapeutics made up 0.43% of Bellevue Group's portfolio in Q2 2026, its #52 holding.
  • 215 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.